Benoît You

11.3k total citations
231 papers, 3.3k citations indexed

About

Benoît You is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Benoît You has authored 231 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 77 papers in Reproductive Medicine and 55 papers in Surgery. Recurrent topics in Benoît You's work include Ovarian cancer diagnosis and treatment (77 papers), PARP inhibition in cancer therapy (33 papers) and Intraperitoneal and Appendiceal Malignancies (29 papers). Benoît You is often cited by papers focused on Ovarian cancer diagnosis and treatment (77 papers), PARP inhibition in cancer therapy (33 papers) and Intraperitoneal and Appendiceal Malignancies (29 papers). Benoît You collaborates with scholars based in France, United States and United Kingdom. Benoît You's co-authors include Gilles Freyer, Julien Péron, Hui Gan, Denis Maillet, Eric X. Chen, Michel Tod, Olivier Colomban, Émilie Hénin, Olivier Gléhen and François Golfier and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Benoît You

218 papers receiving 3.3k citations

Peers

Countries citing papers authored by Benoît You

Since Specialization

Citations

This map shows the geographic impact of Benoît You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benoît You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benoît You more than expected).

Fields of papers citing papers by Benoît You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benoît You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benoît You. The network helps show where Benoît You may publish in the future.

Co-authorship network of co-authors of Benoît You

This figure shows the co-authorship network connecting the top 25 collaborators of Benoît You. A scholar is included among the top collaborators of Benoît You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benoît You. Benoît You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin 2025 ·European Journal of Cancer ·(unknown), (unknown), Sylvie Chabaud, (unknown), (unknown), Aude Fléchon, Helen Boyle, Armelle Vinceneux, F. Bérard, Benoît You, Gilles Freyer, (unknown), Sophie Tartas, Mona Amini‐Adlé	1
2	Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial 2025 ·Nature Communications ·Max Piffoux, Alexandra Léary, Philippe Follana, Cyril Abdeddaim, Florence Joly, Sylvie Bin, (unknown), Anaïs Boulai, Céline Callens, Laurent Villeneuve, (unknown), Vérane Schwiertz, Gilles Freyer, Manuel Rodrigues, Benoît You	1
3	ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma 2025 ·Journal of Clinical Oncology ·Joyce F. Liu, Nicoletta Colombo, Amit M. Oza, Jean‐Sébastien Frenel, Bradley R. Corr, Maria M. Rubinstein, Nicole Nevadunsky, Stéphanie Lheureux, Lydia Gaba, Lucía González Cortijo, Vanda Salutari, Benoît You, Sarah Chiang, Mark J. O’Connor, (unknown), Didier Meulendijks, (unknown), Dana Ghiorghiu, Ana Oaknin	5
4	Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma 2024 ·European Journal of Obstetrics & Gynecology and Reproductive Biology ·(unknown), (unknown), Mojgan Devouassoux‐Shisheboran, Benoît You, Christine Rousset‐Jablonski, (unknown), Touria Hajri, (unknown), Olivier Gléhen, Charles‐André Philip, G. Lamblin, François Golfier, Pierre‐Adrien Bolze	1
5	Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer 2024 ·British Journal of Cancer ·Robert D. Morgan, Xin Wang, (unknown), (unknown), (unknown), (unknown), Jurjees Hasan, Claire Mitchell, Zena Salih, Sudha Desai, Joseph Shaw, Brett Winter‐Roach, Hélene Schlecht, George J. Burghel, Andrew R. Clamp, Richard J. Edmondson, Benoît You, D. Gareth Evans, Gordon C. Jayson, Stephen S. Taylor	5
6	730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA 2024 ·Annals of Oncology ·Guillaume Beinse, Valérie Taly, Alexandra Léary, (unknown), Olivier Trédan, Benoît You, Manuel Rodrigues, (unknown), (unknown), (unknown), (unknown), Coriolan Lebreton, Emilie Kalbacher, P. Fournel, Jean‐Sébastien Frenel, Frédèric Selle, R. Largillier, (unknown), (unknown), Jérôme Alexandre	1
7	Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort 2024 ·Clinical Cancer Research ·Pauline Corbaux, Gilles Freyer, Olivier Gléhen, Benoît You, Naoual Bakrin, (unknown), (unknown), Christophe Sajous, Max Piffoux, Julien Péron, (unknown), Léa Payen, Vahan Képénékian	3
8	Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets. 2024 ·Journal of Clinical Oncology ·Benoît You, Anna Fagotti, Olivier Colomban, Diana Giannarelli, Félix Blanc‐Durand, Giovanni Scambia, (unknown), Domenica Lorusso, Éric Pujade-Lauraine, (unknown), Gaëtan De Rauglaudre, (unknown), Isabelle Laure Ray-Coquard, (unknown), (unknown), (unknown), Gwénaël Ferron, (unknown), Alexandra Léary, Cláudia Marchetti	0
9	A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Sara Bouberhan, Konstantinos Papadimitriou, Rebecca C. Arend, (unknown), Roisin E. O’Cearbhaill, David M. O’Malley, Benoît You, Antonio González-Martı́n, Judith Michels, Linda Mileshkin, Yeh Chen Lee, (unknown), Suk‐Young Yoo, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	7
10	Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA 2024 ·JCO Clinical Cancer Informatics ·(unknown), Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, Oliver Sartor, Gilles Freyer, Benoît You	2
11	Morbidity, mortality, and prognostic factors in gestational trophoblastic neoplasia with liver metastasis 2023 ·Journal of Gynecology Obstetrics and Human Reproduction ·(unknown), (unknown), Touria Hajri, Jérôme Massardier, Benoît You, Jean‐Pierre Lotz, Pascal Rousset, Jérémie Tordo, Mojgan Devouassoux‐Shisheboran, François Golfier, Pierre‐Adrien Bolze	2
12	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers 2022 ·Cancers ·L. Collet, Julien Péron, Frédérique Penault‐Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, Benoît You	7
13	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel 2022 ·Cancers ·(unknown), Réza Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoît You, Stéphane Oudard	4
14	CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study 2022 ·Journal of Clinical Oncology ·Benoît You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter Ansell, Minh H. Dinh, Katherine M. Bell‐McGuinn, (unknown), Gini F. Fleming, Michael Friedländer, Michael A. Bookman, Kathleen N. Moore, Karina Dahl Steffensen, Robert L. Coleman, Elizabeth M. Swisher	20
15	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial 2020 ·Journal of Clinical Oncology ·Benoît You, Pierre‐Adrien Bolze, Jean‐Pierre Lotz, Jérôme Massardier, Laurence Gladieff, Florence Joly, Touria Hajri, Delphine Maucort‐Boulch, Sylvie Bin, Pascal Rousset, Mojgan Devouassoux‐Shisheboran, Adeline Roux, (unknown), (unknown), Carole Langlois‐Jacques, (unknown), Laurent Villeneuve, Gilles Freyer, François Golfier	75
16	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study 2019 ·Clinical Cancer Research ·Olivier Colomban, Michel Tod, Alexandra Léary, Isabelle Ray‐Coquard, Alain Lortholary, (unknown), Jacobus Pfisterer, Andreas du Bois, Christian Kurzeder, Alexander Burges, Julien Péron, Gilles Freyer, Benoît You	37
17	Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC) 2018 ·Cancer Research ·S. M. Domchek, Sophie Postel‐Vinay, Y-J. Bang, YH Park, Jérôme Alexandre, J.P. Delord, Antoîne Italiano, Benoît You, Susan E.P. Bastian, Matthew Krebs, Dawei Wang, Saiama N. Waqar, Helen K. Angell, Maria Learoyd, Shan‐Chwen Chang, Christopher Gresty, Pia Herbolsheimer, Bella Kaufman	41
18	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients 2018 ·Cancer Chemotherapy and Pharmacology ·Olivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, Olivier Colomban, Jérôme Guitton, Vérane Schwiertz, Véronique Régnier Denois, Benoît You, Florence Ranchon, (unknown), Pascal Girard, Franck Chauvin, Gilles Freyer, Michel Tod, Émilie Hénin, V. Trillet-Lenoir	15
19	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review 2013 ·Journal of Clinical Oncology ·Julien Péron, Denis Maillet, Hui Gan, Eric X. Chen, Benoît You	90
20	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Nicolás Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, P. Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), V. Trillet-Lenoir	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact